

Pakistan

Support for Vaccine: Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme

1. **Country:** Pakistan
2. **Vaccine grant number:** PAK-IPV-R
3. **Date of Decision Letter:** 22 January 2021
4. **Date of the Partnership Framework Agreement:** 19 May 2015
5. **Programme title:** New Vaccine Support (NVS), Inactivated Polio Vaccine (IPV), Routine, 2 doses
6. **Vaccine type:** Inactivated Polio Vaccine (IPV)
7. **Requested product presentation and formulation of vaccine:**
IPV, 10 doses/vial, liquid
8. **Programme duration:¹** 2015-2021

9. **Programme Budget (indicative):²** (subject to the terms of the Partnership Framework Agreement, if applicable)

	2015-2020	2021	2022	2023	2024	2025	Total ²
Programme Budget(US\$)	51,341,665	37,068,453	-	-	-	-	88,410,118

10. **Vaccine introduction grant:**

Approval		
Year	Grant number	Amount (US\$)
2015	PAK-IPV-R-VIG-UNIC	935,079
2015	PAK-IPV-R-VIG-UNIC S	724,415
2015	PAK-IPV-R-VIG-WHO	1,761,400

11. **Product switch grant:**

¹This is the entire duration of the programme.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

³This is the amount that Gavi has approved.

Approval		
Year	Grant number	Amount (US\$)
2021	PAK-IPV-R-PSG	1,801,128

12. **Indicative annual amounts:**³ (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2015-2020	2021	2022
Number of vaccine doses	-	17,430,000	-
Number of AD syringes	-	15,570,200	-
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	171,300	-
Annual Amounts (US\$)	51,341,665	37,068,453	-

13. **Procurement agency:** UNICEF Supply Division

14. **Self-procurement:**

Not applicable

15. **Co-financing obligations:**

Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.

16. **Operational support for campaigns:**

Not applicable

17. **Additional Reporting Requirements:**

Reports and other information :	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
<ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March</p> <p>15 May</p>

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
---	------------------------------------

18. Financial clarifications:

Not applicable

19. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,

On behalf of Gavi



Pascal Bijleveld
Director, Country Support
24 January 2021